Seeking Alpha

Despite an earlier downgrade to Market Perform by RBC this morning, Wells Fargo says Celgene...

Despite an earlier downgrade to Market Perform by RBC this morning, Wells Fargo says Celgene (CELG -0.6%) looks attractive at current levels. After meeting with management, Wells says it's pleased with the way Q2 is going and thinks the stock could rally on the back of the E.U.'s label decision on Revlimid, and that the drug is positioned for solid growth.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs